Research
Hormonal
GLP-1 receptor agonists (e.g., semaglutide) and dual agonists (e.g., tirzepatide) are effective pharmacotherapies for obesity, achieving 10-20% mean body weight reduction, but their use is limited by stigma, regulatory barriers, and lack of insurance coverage.
If you have obesity, ask your doctor about GLP-1 receptor agonists (like semaglutide) or dual agonists (like tirzepatide). These are proven to help with significant weight loss. If insurance doesn't cover them, advocate for policy changes or look for patient assistance programs.
StrongSupportsHIGH confidence
Weight loss efficacy of anti-obesity medications has markedly improved, with newer agents achieving 10% to 20% mean body weight reduction in clinical trials. Nevertheless, obesity pharmacotherapy remains underutilized due to stigma, regulatory barriers, and limited insurance coverage.
Why this rating
Based on cited landmark trials (STEP, SURMOUNT series).
Source
Differences between Type 2 Diabetes Mellitus and Obesity Management: Medical, Social, and Public Health Perspectives
Soo Lim et al. · Diabetes & Metabolism Journal · 2025
DOI 10.4093/dmj.2025.0278
narrative_reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity should be managed as a chronic, relapsing disease with long-term structured medical interventions (pharmacotherapy, surgery, behavioral therapy) rather than relying on short-term lifestyle changes, mirroring the established management model for Type 2 Diabetes Mellitus (T2DM).Good
- Obesity lacks standardized diagnostic criteria and treatment targets compared to T2DM, leading to inconsistent care, underdiagnosis, and undertreatment.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →